Novasenta, a Pittsburgh, PA-based biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, raised $40M in Series A funding.
The round was led by UPMC Enterprises.
The company intends to use the funds to advance its pipeline of antibody-based therapeutics and expand its proprietary computational platforms for target discovery, while continuing to recruit top talent.
Co-founded in late 2018 by Robert Ferris, M.D., Ph.D., Dario Vignali, Ph.D., and Greg Delgoffe, Ph.D., all of the UPMC Hillman Cancer Center and the University of Pittsburgh, Novasenta is focused on the discovery of novel therapeutic targets to develop innovative and effective treatments with the goal of transforming the lives of patients with cancer. The company has developed a proprietary platform for single-cell RNA based analysis of high-quality, human tumor samples and combined it with its advanced data mining and target validating abilities to accelerate the path from discovery to drug development. The company’s pipeline includes three programs representing the next generation of immuno-oncology targets and drug candidates.
FinSMEs
01/08/2022